Results 21 to 30 of about 7,028 (198)

Efficacy and safety of abrocitinib and upadacitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: A systematic review and meta-analysis

Heliyon, 2023
Background: The sparsity of head-to-head trials for medications used as in atopic dermatitis (AD) treatment makes therapy options difficult. Objective: To better compare the efficacy and safety of abrocitinib and upadacitinib with dupilumab in patients ...
Qin Gao, Yanxia Zhao, Junling Zhang
doaj   +1 more source

Amenorrhea in an Adolescent Female as a Rare Adverse Event of Upadacitinib Treatment for Atopic Dermatitis [PDF]

Patient Preference and Adherence
Yan Teng, Yi Tang, Yibin Fan, Xiaohua Tao,* Yang Ding* Center for Plastic & Reconstructive Surgery, Department of Dermatology, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital of Hangzhou Medical College, Hangzhou, People’s ...
Teng Y, Tang Y, Fan Y, Tao X, Ding Y
doaj   +2 more sources

Atopic Dermatitis and Ulcerative Colitis Successfully Treated with Upadacitinib [PDF]

, 2023
Background and Objectives: JAK inhibitors entered current clinical practice as treatment for several immune-related diseases and, recently, for atopic dermatitis.
Martina Caviglia, Ester Del Duca, Nicolò Sini, Giovanni Pellacani, Grieco, Teresa, Giuseppina Cusano, Taliano, Alberto, Alvise Sernicola, Caviglia, Martina, Carmen Cantisani, Sini, Nicolò, Sernicola, Alvise, Cantisani, Carmen, Del Duca, Ester, Cusano, Giuseppina, Camilla Chello, Chello, Camilla, Ianiro, Gianluca, Alberto Taliano, Teresa Grieco, Gianluca Ianiro, Pellacani, Giovanni   +21 more
core   +7 more sources

Acne Among Japanese Patients with Atopic Dermatitis Receiving Upadacitinib in the Phase 3 Rising Up Study

Dermatology and Therapy, 2023
Introduction Upadacitinib, an oral selective Janus kinase (JAK) inhibitor, is used to treat moderate-to-severe atopic dermatitis (AD). Acne is the most common treatment-emergent adverse event in patients with AD treated with upadacitinib.
Nobukazu Hayashi, Masanori Ikeda, John Liu, Eliza Raymundo, Yingyi Liu, Takuya Sasaki, Kenshi Yamasaki   +6 more
doaj   +1 more source

Upadacitinib for psoriatic arthritis refractory to biologics : SELECT-PsA 2 [PDF]

, 2020
Background: Upadacitinib is a Janus kinase inhibitor under evaluation for the treatment of psoriatic arthritis (PsA). We evaluated upadacitinib in patients with PsA and prior inadequate response or intolerance to at least one biologic disease-modifying ...
Pangan, Aileen L., Pangan, Aileen L, Papp, Kim, Wang, Xin, Lertratanakul, Apinya, Mease, Philip J., Dokoupilova, Eva, Van den Bosch, Filip, McCaskill, Reva M, Tillett, William, Anderson, Jaclyn K., Zueger, Patrick, Tsuji, Shigeyoshi, Keiserman, Mauro, McCaskill, Reva M., Anderson, Jaclyn K, Zhong, Sheng, Mease, Philip   +17 more
core   +1 more source

Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension

RMD Open, 2022
Introduction Long-term safety and efficacy of upadacitinib in patients with active ankylosing spondylitis (AS) has not been previously reported.Methods In SELECT-AXIS 1, patients receiving placebo were switched to upadacitinib 15 mg once daily at week 14
Désirée van der Heijde, Filip van den Bosch, Atul Deodhar, Joachim Sieper, Bernard Combe, Walter P Maksymowych, In-Ho Song, Tae-Hwan Kim, Mitsumasa Kishimoto, Yuanyuan Duan, Yunxia Sui, Andrew J Östör, Peter K Wung   +12 more
doaj   +1 more source

Safety profile of upadacitinib in rheumatoid arthritis: Integrated analysis from the SELECT phase III clinical programme [PDF]

, 2021
Objectives: This integrated analysis presents the safety profile of upadacitinib, a Janus kinase inhibitor, at 15 mg and 30 mg once daily in patients with moderately to severely active rheumatoid arthritis (RA). Methods: Treatment-emergent adverse events
Bessette, Louis, Cohen, Stanley B., Zerbini, Cristiano A. F., Burmester, Gerd R., Winthrop, Kevin L., Zhang, Ying, Hendrickson, Barbara, van Vollenhoven, Ronald F., Enejosa, Jeffrey V., Tanaka, Yoshiya, Khan, Nasser   +10 more
core   +1 more source

Disease Control with Upadacitinib in Patients with Psoriatic Arthritis: A Post Hoc Analysis of the Randomized, Placebo-Controlled SELECT-PsA 1 and 2 Phase 3 Trials [PDF]

, 2022
INTRODUCTION: Low disease activity (LDA)/remission is the target of treatment in patients with psoriatic arthritis (PsA). We assessed the proportions of patients with PsA receiving upadacitinib who achieved LDA/remission over 1 year.
Douglas, Kevin, Soriano, Enrique R, Lertratanakul, Apinya, Lippe, Ralph, Feng, Dai, Gladman, Dafna, Kavanaugh, Arthur, FitzGerald, Oliver, Gossec, Laure, Soriano, Enrique R., Nash, Peter, Mease, Philip   +11 more
core   +1 more source

Safety of upadacitinib in moderate-to-severe atopic dermatitis: An integrated analysis of phase 3 studies [PDF]

, 2022
BACKGROUND: Upadacitinib is a selective, reversible, Janus kinase (JAK) inhibitor with established efficacy in moderate-to-severe atopic dermatitis (AD). OBJECTIVE: Evaluate the safety of upadacitinib in patients with moderate-to-severe AD.
Silverberg, Jonathan I, Chih-ho Hong, H., Tenorio, Allan R., Thyssen, Jacob P, Thyssen, Jacob P., Hendrickson, Barbara, Chu, Alvina D., Irvine, Alan D., Silverberg, Jonathan I., Papp, Kim A., Guttman-Yassky, Emma, Paller, Amy S., Papp, Kim A, Chu, Alvina D, Tenorio, Allan R, Liu, John, Irvine, Alan D, Ladizinski, Barry, Dilley, Deanne, Paller, Amy S, Weidinger, Stephan, Hong, H Chih-Ho   +21 more
core   +1 more source

Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: Results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up) [PDF]

, 2023
BackgroundCharacterization of upadacitinib use and switching from dupilumab to upadacitinib among patients with moderate-to-severe atopic dermatitis (AD) is needed.ObjectiveTo evaluate the long-term safety and efficacy of continuous upadacitinib 30 mg ...
Kaplan, Blair, Xiaofei Hu, John Liu, Blauvelt, Andrew, Eisman, Samantha, Liu, Yingyi, Tianshuang Wu, Brian M. Calimlim, Hu, Xiaofei, Alison Fischer, Prajapati, Vimal H., Vimal H. Prajapati, Kilian Eyerich, Calimlim, Brian M., Teixeira, Henrique D., Laquer, Vivian, Andrew Blauvelt, Blair Kaplan, Yingyi Liu, Barry Ladizinski, Fischer, Alison, Vivian Laquer, Henrique D. Teixeira, Liu, John, Ladizinski, Barry, Wu, Tianshuang, Samantha Eisman, Eyerich, Kilian   +27 more
core   +1 more source